7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
20 citations
,
January 2000 in “Dermatologic Clinics” New psoriasis treatments are effective but come with side effects and risks.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
1 citations
,
June 1999 in “American Journal of Contact Dermatitis” Tazarotene gel is more effective for acne than tretinoin and works as well as adapalene.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
February 2023 in “JAAD case reports” Reducing immunosuppression and using antiviral creams improved the woman's skin condition.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
February 2026 in “Journal of Drugs in Dermatology” Dupilumab helped a 13-year-old regrow hair after alopecia totalis.
1 citations
,
October 2017 JAK inhibitors are effective for hair regrowth in severe alopecia areata.
11 citations
,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
3 citations
,
July 2018 in “European Journal of Dermatology” An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
Baricitinib shows promise for treating alopecia areata with mild side effects.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
10 citations
,
April 1964 in “Journal of the American Geriatrics Society” Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
May 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
5 citations
,
January 2024 in “Therapeutic Advances in Hematology” Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.